| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Protagonist Therapeutics, Inc. (PTGX) has 8 insiders with recent SEC Form 4 filings, including 0 buys and 19 sells. PTGX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 523.5K | $59.99M | - | |
| Other | 106.8K | $12.24M | - | |
| CFO | 60.8K | $6.96M | - | |
| Dir | 7.8K | $896.7K | - | |
| Dir | 7.8K | $896.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2019 | Shames Richard S. | Chief Medical Officer | Sell | 657 | $8.03 | $5,275.71 | -2.0% | |
| Feb 6, 2019 | Patel Dinesh V Ph D | President And CEO | Sell | 10,909 | $7.74 | $84,409.94 | -1.5% | |
| Feb 6, 2019 | Liu David Y | Chief Scientific Officer | Sell | 3,821 | $7.74 | $29,561.55 | -9.4% | |
| Feb 6, 2019 | Shames Richard S. | Chief Medical Officer | Sell | 2,778 | $7.74 | $21,505.50 | -5.2% | |
| May 17, 2018 | Canaan X L.P. | 10% Owner | Sell | 38,968 | $6.09 | $237,357.98 | -1.8% | |
| May 16, 2018 | Canaan X L.P. | 10% Owner | Sell | 164,747 | $6.42 | $1,058,374.50 | -2.4% | |
| Mar 23, 2018 | Canaan X L.P. | 10% Owner | Sell | 59,950 | $20.71 | $1,241,324.70 | -2.5% | |
| Mar 22, 2018 | Canaan X L.P. | 10% Owner | Sell | 39,518 | $20.61 | $814,398.15 | -0.5% | |
| Mar 19, 2018 | Canaan X L.P. | 10% Owner | Sell | 20,365 | $20.55 | $418,508.25 | -0.4% | |
| Mar 15, 2018 | Canaan X L.P. | 10% Owner | Sell | 13,155 | $20.66 | $271,768.43 | -0.2% |